KYNB

NASDAQ 已收盘

Kyntra Bio

1.56 USD
▼-0.27-14.75%
盘后 1.56 +0.31%
2026-11-20
市值
$6.32M
市盈率
0.08
EPS
-4.27
股息率
—
52 周区间
1.56 – 10.47
成交量
37.38K
Beta
1.11
目标价
22.75
52W 低 1.5652W 高 10.47
价格走势

公司简介

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United ...